
Entera Bio Ltd. ENTX
$ 1.15
-1.71%
Annual report 2020
added 08-19-2023
Entera Bio Ltd. Long Term Debt Current 2011-2026 | ENTX
Annual Long Term Debt Current Entera Bio Ltd.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 189 K | 177 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 189 K | 177 K | 183 K |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
ACADIA Pharmaceuticals
ACAD
|
9.96 M | $ 22.57 | 0.04 % | $ 3.74 B | ||
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | ||
|
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | ||
|
Allakos
ALLK
|
3.25 M | - | - | $ 28.6 M | ||
|
Akebia Therapeutics
AKBA
|
3.55 M | $ 1.41 | -1.4 % | $ 363 M | ||
|
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M | ||
|
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
Applied Therapeutics
APLT
|
429 K | - | - | $ 8.42 M | ||
|
Aravive
ARAV
|
2.2 M | - | -13.39 % | $ 1.45 M | ||
|
BioNTech SE
BNTX
|
45 M | $ 91.98 | -0.11 % | $ 27.2 B | ||
|
Aytu BioScience
AYTU
|
137 K | $ 2.56 | -3.76 % | $ 16.1 M | ||
|
AstraZeneca PLC
AZN
|
382 M | - | - | $ 96.9 B | ||
|
Alterity Therapeutics Limited
ATHE
|
57.6 K | $ 3.85 | -1.39 % | $ 9.26 B | ||
|
AVROBIO
AVRO
|
878 K | - | 1083.1 % | $ 745 M | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
7.93 M | $ 20.87 | 2.3 % | $ 976 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
208 K | - | -2.5 % | $ 5.88 M | ||
|
Aquestive Therapeutics
AQST
|
631 K | $ 4.17 | -0.24 % | $ 446 M | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | ||
|
Arcutis Biotherapeutics
ARQT
|
294 K | $ 24.57 | -0.16 % | $ 3.13 B | ||
|
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B | ||
|
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
CymaBay Therapeutics
CBAY
|
7 K | - | - | $ 3.45 B | ||
|
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | ||
|
Cabaletta Bio
CABA
|
3.46 M | $ 3.17 | 2.59 % | $ 319 M | ||
|
Codiak BioSciences
CDAK
|
2.66 M | - | -55.98 % | $ 2.15 M | ||
|
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | ||
|
Avid Bioservices
CDMO
|
1.35 M | - | - | $ 789 M | ||
|
Cidara Therapeutics
CDTX
|
1.38 M | - | - | $ 1.41 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 2.93 | -4.87 % | $ 6.38 B | ||
|
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | ||
|
Celldex Therapeutics
CLDX
|
1.55 M | $ 33.62 | 3.73 % | $ 2.23 B | ||
|
Concert Pharmaceuticals
CNCE
|
1.16 M | - | - | $ 401 M | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
Celsion Corporation
CLSN
|
406 K | - | -6.63 % | $ 13.9 M | ||
|
Allena Pharmaceuticals
ALNA
|
317 K | - | 3.16 % | $ 1.9 M |